Honored to speak Stanford Department of Medicine MGR on Wed Sept 4th, 8am PDT & to lead off this series of #WomeninMedicineMonth My presentation title is “Who controls the past controls the future: our aging blood cells & molecular cancer prevention” Stanford Hematology Division #WIMmonth2024 StanfordMedRes

Applications for Centenary’s Summer Research Scholarship program are now open. Projects in a variety of research fields across our seven centres are available. To see this year's projects and to apply go to: centenary.org.au/2024-summer-re… #UTS #USYD

The third Cambridge Lymphoma Biology International Symposium will bring together research scientists & clinicians with an interest in the biology of lymphoma and CLL. Held on 17-18 September 2024 at Magdalene College, Cambridge. ow.ly/WpMx50T8z5Y

Congrats to our IELSG colleagues on their fantastic new publication! ⬇️

Calling all parents! Did you know that childcare at #ASH24 is complimentary? ASH has arrangements with KiddieCorp to provide childcare at #ASH24 from December 6-December 10. Register your child by November 15 as space is limited! Learn more & register: ow.ly/U2x250Suxby

Just published (& a privilege to be involved in the discussions) HIV-associated lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ow.ly/xZ8v50TcXLL ESMO - Eur. Oncology European Hematology Association

Ibrutinib plus rituximab and mini-CHOP in very elderly patients with newly diagnosed DLBCL: A phase II ALLG study ashpublications.org/bloodadvances/…

👏 Judith Trotman #EmmaVerner Australasian Leukaemia & Lymphoma Group (ALLG) #DLBCL #lymphoma #lymsm

Register now for the hybrid Lymphoma Breakfast Meeting to hear project updates on improving lymphoma patient outcomes! Breakfast will be served for in-person attendees ➡️🥑🍞 Australasian Lymphoma Alliance Lymphoma and Related Diseases Registry Lymphoma Australia eventbrite.com.au/e/alalardrla-l…

Evaluation of coverage, generalisability and validity of the U-CAN lymphoma biobank in Sweden: A comparison with nationwide registers Ingrid Glimelius #Elin Forsgren #Sara Ekberg #Karin Smedby & colleagues onlinelibrary.wiley.com/doi/full/10.11…

CONGRESS | POSTER | #SOHO2024 | Stephen Schuster Penn presented 3-year follow-up updates from a pivotal phase II study of mosenutuzumab in heavily pretreated R/R FL (N=90). Long-lasting remissions were achieved, with 3-year PFS and OS stable and estimated 30-month DOR rate 72.7%

CONGRESS | POSTER | #SOHO2024 | Yasmin Karimi Yasmin Karimi presents extended follow-up data beyond 2.5 years from the pivotal expansion cohort of the phase II EPCORE NHL-1 study of epcoritamab monotherapy in R/R #DLBCL (N=157). Of pts with a CR (n=65) 54% remained in CR at 30

Limited stage DLBCL #SOHO2024 #lymphoma By Olivia

Another remarkably similar case of T-cell lymphoma after CAR19 therapy. nejm.org/doi/full/10.10… We catalogued the 8 thus deeply profiled cases here with Mark Hamilton, Takeshi Sugio, Troy Noordenbos, and David Miklos

With much gratitude #IFLI i-fli.org supporting WiL's upcoming webinar series (Oct/Nov '24) cdn.prod.website-files.com/65bff97f5937b9… #Pharma please connect with us to find out how to support #WiL's global education initiatives! #IndolentLymphoma #FollicularLymphoma #lymphoma

📚 🩸 Calling all residents preparing to apply for a fellowship! The application for the ASH Hematology-Focused Fellowship Training Program (HFFTP) is still open! Learn more about the HFTTP program and all the benefits here: ow.ly/akg150Soyvb #Hematology #MedEd #MedTwitter

Patients excluded from clinical trials of DLBCL are at a higher risk of dying from lymphoma when treated with standard-of-care therapy. ow.ly/Ihbt50T8HsO #healthservicesandoutcomes #lymphoidneoplasia

Gracias x la invitación Beatriz Wills. Respecto a la pregunta: no hay q correr antes de caminar! Es importante 1ero asegurar el acceso a rituximab, TACPH y bendamustina que aun es heterogéneo en los países de latam y dentro de un mismo país (privado vs publico).

A novel combination therapy has induced durable remissions in relapsed patients with specific molecular #DLBCL subtypes with mainly reversible adverse events. ow.ly/Uhkb50TfWup

CAR T-cell in NHL- Summary and Conclusion- Jason Westin, MD FACP #CARTcell #lymsm #SOHO24 #SOHO2024